Compare MYO & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MYO | ELOX |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.8M | 52.5M |
| IPO Year | 2017 | 2013 |
| Metric | MYO | ELOX |
|---|---|---|
| Price | $1.23 | $12.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $4.64 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 215.2K | 21.3K |
| Earning Date | 11-09-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,000,000.00 | N/A |
| Revenue This Year | $13.25 | N/A |
| Revenue Next Year | $10.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40814.79 | N/A |
| 52 Week Low | $0.61 | $10.00 |
| 52 Week High | $1.89 | $23.40 |
| Indicator | MYO | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 44.56 |
| Support Level | $1.17 | $12.47 |
| Resistance Level | $1.75 | $14.65 |
| Average True Range (ATR) | 0.11 | 0.95 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 22.58 | 54.27 |
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.